NCT00889603

Non-Interventional Study With Aricept® Evess

Non-Interventional Study With Aricept® Evess In Patients Diagnosed With Mild And Moderate Alzheimer's Disease Or Vascular Dementia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 370 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The Aricept® Evess study is a prospective, non-comparative, non-interventional study on use of Aricept® Evess in the treatment of out-patients with AD and Vascular Dementia. The 24 week length of the study aims to collect data from a large number of patients (n= 400) on the safety and efficacy at the usual dosage of the product providing an overview of Aricept® Evess profile.

Conditions

• Alzheimer's Disease
• Vascular Dementia

Interventions

Type	Name	Description
DRUG	Aricept® Evess	5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets. Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing).

Timeline

• Start date: 2009-05-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2009-04-29
• Last updated: 2011-03-31
• Results posted: 2011-03-31

Locations

12 sites across 1 country: Romania